anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a hair treating agent composition, capable of imparting a bright color tone and a good gloss to hair and especially suitable for fixing permanent wave hair by making the composition contain hydrogen peroxide therein. SOLUTION: This hair treating agent composition contains 0.5-12wt.% hydrogen peroxide and has 1,000-10,000mPa.s viscosity at 25 deg.C. Furthermore, a direct dye in an amount of 0.001-2.5wt.% is preferably contained therein and a natural or a synthetic polymer in an amount of 0.1-2.5wt.% is preferably compounded for the purpose of conditioning hair. A well-known ingredient is suitably further compounded and the pH is regulated to 3-7. The composition is capable of providing hair, having a good gloss and a moderate elasticity and excellent in combing properties and pliability. When a dye is compounded therein, hair tinged with a bright color tone is obtained.
BACKGROUND: Statins are widely used for treating patients with ischemic stroke at risk of secondary cerebrovascular events. It is unknown whether Asian populations benefit from more intensive statin-based therapy for stroke recurrence. Therefore, in the present study we evaluated the effectiveness and safety of high-dose and moderate-dose statins for patients who had experienced mild ischemic stroke during the acute period.
METHODS AND RESULTS: This multicenter prospective study included patients with mild ischemic stroke who presented within 72 hours of symptom onset. The outcomes of patients in the high-intensity and moderate-intensity statin treatment groups were compared, with the main efficacy outcome being stroke recurrence and the primary safety end point being intracranial hemorrhage. The propensity score matching method was employed to control for imbalances in baseline variables. Subgroup analyses were conducted to evaluate group differences. In total, the data of 2950 patients were analyzed at 3 months, and the data of 2764 patients were analyzed at 12 months due to loss to follow-up. According to the multivariable Cox analyses adjusted for potential confounders, stroke recurrence occurred similarly in the high-intensity statin and moderate-intensity statin groups (3 months: adjusted hazard ratio [HR], 1.12 [95% CI, 0.85-1.49]; P=0.424; 12 months: adjusted HR, 1.08 [95% CI, 0.86-1.34]; P=0.519). High-intensity statin therapy was associated with an increased risk of intracranial hemorrhage (3 months: adjusted HR, 1.81 [95% CI, 1.00-3.25]; P=0.048; 12 months: adjusted HR, 1.86 [95% CI, 1.10-3.16]; P=0.021). The results from the propensity score-matched analyses were consistent with those from the Cox proportional hazards analysis.
CONCLUSIONS: Compared with moderate-intensity statin therapy, high-dose statin therapy may not decrease the risk of mild, noncardiogenic ischemic stroke recurrence but may increase the risk of intracranial hemorrhage.
REGISTRATION: URL: www.chictr.org.cn/. Unique Identifier: ChiCTR1900025214.
Extended day surgery or 23 h surgery is a surgical model where patients arrive to the hospital from home at the day of surgery, are operated and recover in a 23 h surgery unit. 23H surgery units are usually situated near postoperative recovery unit. THe 23 H surgical model was implemented in Kuopio University Hospital 2015 and between May 2017-May 2018 patients were recruited in the present prospective follow up cohort study. Patients were informed and they gave their informed consent. The patients were contacted two weeks after the study and details of their recovery were asked. Satisfaction to the care in 23 h unit and surgical process, were asked. Amount of readmissions, reoperations, contacts to health care professionals and adverse events are recorded.

Detailed information about intensity of pain, analgesic need and use in the hospital was recorded and pain interference in daily life for short term recovery period was asked.
<P>PROBLEM TO BE SOLVED: To provide a method for using a protein complex including a "ble" fusion protein having a specific bonding characteristic.  <P>SOLUTION: The protein complex can be bonded reversibly to an antibiotic from a bleomycin family, and the characteristic is utilized for various immobilization methods. The complex is used as a marker for protein expression and/or folding, or as a marker for affinity tagging. The invention also provides a probe including an array of an immobilized antibiotic from the bleomycin family, which acts as an analyte capture moiety. In another aspect, a purification media is provided, which includes an antibiotic of the bleomycin family as an analyte capture moiety. Further, a method is provided, for generating a soluble form of an insoluble protein by expressing the protein as a "ble" fusion protein and selecting in the presence of an antibiotic from the bleomycin family. In a further aspect, the "ble" protein is expressed as a fusion protein in a cell into which a labelled antibiotic of the bleomycin family is introduced, thereby allowing identification of the cellular localization of the protein.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A well-conducted review provides quality evidence to inform policy and practice. It is important that the review is as rigorous and as fully reported as possible if the evidence from the review is incorporated into clinical practice. We are writing in response to an article titled, 'Evidence of Knowledge, Attitude, and Practice Regarding Human Papilloma Virus Vaccination at the Community Level in India: A Systematic Review and Meta-Analysis' by Pal et al published in Asian Pacific Journal of Cancer Prevention in March 2024. There are some major methodological flaws in the paper that might have biased the conclusions drawn from the review to inform strategies to improve HPV vaccine uptake by the target population in India. There was clear evidence of substantial heterogeneity (I2=96.0%-100%) among the studies that were included in the meta-analysis. In addition, the outcomes measured were not specific. More ever, the authors did not strictly follow the PRISMA guidelines for screening. Furthermore, the data extraction process and the reasons for language restriction were not clear, all of which could contribute to biased results, lowering the validity of the findings.
PURPOSE:An aldose reductase inhibitor, containing a water or an aqueous organic solvent extract of one or two or more crude drugs selected from Cinnamomi Cortex, Paeoniae Radix, Zizyphi Fructus, Zingiberis Rhizoma, Glycyrrhizae Radix, etc., as an active constituent and capable of reducing accumulation of sorbitol which is a cause for complications of diabetes. CONSTITUTION:An aldose reductase inhibitor containing an extract prepared by extracting one or two or more crude drugs of Cinnamomi Cortex, Paeoniae Radix, Zizyphi Fructus, Zingiberis Rhizoma, Glycyrrhizae Radix, Atractylodis Lanceae Rhizoma and Aconiti Tuber with water or an aqueous organic solvent, e.g. ethanol, or dried extract obtained by filtering the extract and drying the filtrate. The extract may be used as a pharmaceutical of powder, tablet, capsule, etc., according a conventional method. The inhibitor is capable of inhibiting a rate limiting enzyme aldose reductase in a polyol route which a metabolic route of glucose and reducing the accumulation of sorbitol in erythrocytes and treating diabetic complications, e.g. cataract, retinopathy, neuropathy, etc., with high safety.
Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
PURPOSE: A composition for preventing and improving cancer, yogurt and tofu are provided to prevent or improve cancer by including Hypsizigus marmoreus extract. CONSTITUTION: A composition for preventing and improving cancer contains Hypsizigus marmoreus extract acquired by water, ethanol or the mixture of water and ethanol. The Hypsizigus marmoreus extract is obtained after the following steps. The Hypsizigus marmoreus is boiled in the solvent at 50°C or 100°C for 20 hours; eliminates the low molecular materials which has molecular weight under 20kDa; separates neutral polysaccharide; separates acidic polysaccharide. The material for preventing and improving cancer contains 0.01 to 5 weight percentage of the total composition. A cancer preventing and improving yogurt includes 0.1 to 5 weight percentage of the composition. A cancer preventing and improving tofu contains 1 to 10 weight percentage of the composition.
Abusive head trauma (AHT) is a significant cause of morbidity and mortality for infants. Determining when to pursue a complete physical abuse evaluation can be difficult, especially for nonspecific findings or when a child appears clinically well. This retrospective study of 7 cases sought to describe the presentation, evaluation, and diagnoses for infants with abnormal subdural collections identified on cranial ultrasound for macrocephaly, and to determine how frequently AHT is diagnosed. The results of this study showed that while each patient presented due to asymptomatic macrocephaly, the extent of the workup varied greatly. In addition, no infants had suspicious injuries for abuse during the initial evaluation or the year following. In summary, among the 7 patients seen for asymptomatic macrocephaly with possible subdural hemorrhage, there were very inconsistent child abuse workups. There needs to be a standardized clinical guideline for this specific patient population involving a child abuse pediatric evaluation.
BACKGROUND: Cognitive impairment is prevalent across neuropsychiatric disorders but there is a lack of treatment strategies with robust, enduring effects. Emerging evidence indicates that altitude-like hypoxia cognition training may induce long-lasting neuroplasticity and improve cognition. We will investigate whether repeated cognition training under normobaric hypoxia can improve cognitive functions in healthy individuals and patients with affective disorders and the neurobiological underpinnings of such effects.
METHODS: In sub-study 1, 120 healthy participants are randomized to one of four treatment arms in a double-blind manner, allowing for examination of separate and combined effects of three-week repeated moderate hypoxia and cognitive training, respectively. In sub-study 2, 60 remitted patients with major depressive disorder or bipolar disorder are randomized to hypoxia with cognition training or treatment as usual. Assessments of cognition, psychosocial functioning, and quality of life are performed at baseline, end-of-treatment, and at 1-month follow-up. Functional magnetic resonance imaging (fMRI) scans are conducted at baseline and 1-month follow-up, and [11C]UCB-J positron emission tomography (PET) scans are performed at end-of-treatment to quantify the synaptic vesicle glycoprotein 2A (SV2A). The primary outcome is a cognitive composite score of attention, verbal memory, and executive functions. Statistical power of ≥ 80% is reached to detect a clinically relevant between-group difference with minimum n = 26 per treatment arm. Behavioral data are analyzed with an intention-to-treat approach using mixed models. fMRI data is analyzed with the FMRIB Software Library, while PET data is quantified using the simplified reference tissue model (SRTM) with centrum semiovale as reference region.
DISCUSSION: The results will provide novel insights into whether repeated hypoxia cognition training increases cognition and brain plasticity, which can aid future treatment development strategies.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT06121206 . Registered on 31 October 2023.
The present invention relates to a solid hair dye cosmetic composition containing silicon oil and a silicon-based film forming agent and containing a dye using hydroxylapatite and calcined silica, wherein a dyeing effect is temporarily applied to hair. Particularly, the solid hair dye cosmetic composition of the present invention contains 10-50 wt% of silicon oil, 2-10 wt% of a silicon-based film forming agent, 3.0-20.0 wt% of wax, 0.1-5 wt% of hydroxylapatite, 0.05-1.5 wt% of calcined silica, 1.0-30.0 wt % of a dye, 5.0-40.0 wt% of a body color, and 0.2-10.0 wt% of an oil viscosity increasing agent. In the present invention, raw ingredients such as dimethicone, cyclopentasiloxane, methyltrimethicone, cyclohexasiloxane, caprylylmethicone, phenyltrimethicone, and diphenyl dimethicone which have excellent water resistance are used as a main base so that the same has strong resistance against rainwater or sweat. The silicone-based film forming agent is used so that erasion caused by friction or sebum is rare. The hydroxylapatite is mixed and used with the dye so that hair adhesion is improved. Accordingly, a dyeing effect can be maintained for a long time in a desired position. Moreover, the same is clearly washed from hair by means of a washer such as a general shampoo containing a silicon component so that damage to hair can be minimized.
Non-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis process involving various genetic and epigenetic alterations, which essentially contribute to the high incidence of mortality among patients with NSCLC. Clinical observations revealed that NSCLC also co-opts a multifaceted immune checkpoint dysregulation as an important driving factor in NSCLC progression and development. For example, a deregulated PI3K/AKT/mTOR pathway has been noticed in 50-70% of NSCLC cases, primarily modulated by mutations in key oncogenes such as ALK, EGFR, KRAS, and others. Additionally, genetic association studies containing patient-specific factors and local reimbursement criteria expose/reveal mutations in EGFR/ALK/ROS/BRAF/KRAS/PD-L1 proteins to determine the suitability of available immunotherapy or tyrosine kinase inhibitor therapy. Thus, the expression of such checkpoints on tumors and immune cells is pivotal in understanding the therapeutic efficacy and has been extensively studied for NSCLC treatments. Therefore, this review summarizes current knowledge in NSCLC tumorigenesis, focusing on its genetic and epigenetic intricacies, immune checkpoint dysregulation, and the evolving landscape of targeted therapies. In the context of current and future therapies, we emphasize the significance of antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as the primary therapeutic strategy for immune system reactivation in NSCLC. Other approaches involving the promising potential of nanobodies, probodies, affibodies, and DARPINs targeting immune checkpoints are also described; these are under active research or clinical trials to mediate immune regulation and reduce cancer progression. This comprehensive review underscores the multifaceted nature, current state and future directions of NSCLC research and treatment.
Pulmonary fibrosis (PF) is a severe, irreversible lung disease characterized by progressive scarring, with idiopathic pulmonary fibrosis (IPF) being the most prevalent form. IPF's pathogenesis involves repetitive lung epithelial injury leading to fibroblast activation and excessive extracellular matrix (ECM) deposition. The prognosis for IPF is poor, with limited therapeutic options like nintedanib and pirfenidone offering only modest benefits. Emerging research highlights the dysregulation of the yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling pathway as a critical factor in PF. YAP and TAZ, components of the Hippo pathway, play significant roles in cell proliferation, differentiation, and fibrosis by modulating gene expression through interactions with TEA domain (TEAD) transcription factors. The aberrant activation of YAP/TAZ in lung tissue promotes fibroblast activation and ECM accumulation. Targeting the YAP/TAZ pathway offers a promising therapeutic avenue. Preclinical studies have identified potential treatments, such as trigonelline, dopamine receptor D1 (DRD1) agonists, and statins, which inhibit YAP/TAZ activity and demonstrate antifibrotic effects. These findings underscore the importance of YAP/TAZ in PF pathogenesis and the potential of novel therapies aimed at this pathway, suggesting a new direction for improving IPF treatment outcomes. Further research is needed to validate these approaches and translate them into clinical practice.
OBJECTIVE: Among people with peripheral artery disease (PAD), perceived change in walking difficulty over time, compared with people without PAD, is unclear. Among people reporting no change in walking difficulty over time, differences in objectively measured change in walking performance between people with and without PAD are unknown.
METHODS: A total of 1289 participants were included. Eight hundred seventy-four participants with PAD (aged 71.1 ± 9.1 years) were identified from noninvasive vascular laboratories and 415 without PAD (aged 69.9 ± 7.6 years) were identified from people with normal vascular laboratory testing or general medical practices in Chicago. The Walking Impairment Questionnaire and 6-minute walk were completed at baseline and 1-year follow-up. The Walking Impairment Questionnaire assessed perceived difficulty walking due to symptoms in the calves or buttocks on a Likert scale (range, 0-4). Symptom change was determined by comparing difficulty reported at 1-year follow-up to difficulty reported at baseline.
RESULTS: At 1-year follow-up, 31.9% of participants with and 20.6% of participants without PAD reported walking difficulty that was improved (P < .01), whereas 41.2% vs 55%, respectively, reported walking difficulty that was unchanged (P < .01). Among all reporting no change in walking difficulty, participants with PAD declined in 6-minute walk, whereas participants without PAD improved (-10 vs +15 meters; mean difference, -25; 95% confidence interval, -38 to -13; P < .01).
CONCLUSIONS: Most people with PAD reported improvement or no change in walking difficulty from calf or buttock symptoms at one-year follow-up. Among all participants who perceived stable walking ability, those with PAD had significant greater declines in objectively measured walking performance, compared with people without PAD.
BACKGROUND: Autologous fat transfer (AFT) has been proposed as a possible treatment for scar tissue and its associated symptoms. Its effectiveness's evidence is yet unidentified though. The aim of this meta-analysis is to evaluate the currently available evidence on the efficacy and safety of autologous fat transfer in treating post-burn and post-traumatic scars using a validated scar measurement tool.
METHODS: This study performed a systematic literature review in November 2023 using the following electronic databases: MEDLINE, SCOPUS, Directory of Open Access Journals (DOAJ), PUBMED, and Google Scholar. The following key terms were included: (Fat grafting OR Autologous fat transfer) AND (body scars OR body burns OR body wounds) AND (Efficacy OR Safety OR satisfaction). We evaluated articles according to predefined quality criteria. The following data were included during the extraction period: patient demographics, indications for AFT, the number of AFT sessions, follow-up periods, and changes in the Patient and Observer Scar Assessment Scale (POSAS) scores, which contain both the patient and observer components.
RESULTS: This study included 1326 patients and 23 published articles. A total of 14 prospective studies, 7 retrospective studies, and 2 Randomized clinical trials studies were evaluated. These 23 articles came from diverse global locations; the earliest was published in 1992, and the most recently published in 2022.
CONCLUSION: Our findings demonstrated significant enhancements in scar characteristics from both patient and observer perspectives. Overall, AFT holds promise as a valuable treatment option for scar-related conditions as it enhances scar quality ,contributing to improved patient outcomes and satisfaction.
LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to Table of Contents or the online Instructions to Authors www.springer.com/00266.
Patient inclusion in this study will be proposed 60 to 1-days period preceding the surgical procedure. The patient will be randomized in the crude PTFE or in the Propaten groups. Regarding the intervention, the technique used during the therapeutic procedure shall be left to the operator's discretion, except the type of the graft. Demographic, intraoperative and postoperative data will be collected prospectively. Patient will be assessed and followed up according a current care. The cost difference between both groups will be identified.
PURPOSE: A composition containing Aster ageratoides extract for preventing or treating diabetes complication is provided to ensure antioxidation without side effects. CONSTITUTION: A composition for preventing or treating diabetes complication contains Aster ageratoides extract as an active ingredient. The Aster ageratoides extract is isolated using water, alcohol of 1-5 carbon atoms, or mixture thereof. A food composition for preventing or treating diabetes complication contains the Aster ageratoides leaf extract as an active ingredient. The food composition is a food, food additive, beverage, or beverage additive. The dairy dose of the composition is 0.1mg/kg(weight)-500 mg/kg(body weight).
Acinetobacter baumannii is one of the most prevalent causes of nosocomial infections worldwide. However, a paucity of information exists regarding the connection between metabolic capacity and in vivo bacterial fitness. Elevated lactate is a key marker of severe sepsis. We have previously shown that the putative A. baumannii lactate permease gene, lldP, is upregulated during in vivo infection. Here, we confirm that lldP expression is upregulated in three A. baumannii strains during a mammalian systemic infection. Utilising a transposon mutant disrupted for lldP in the contemporary clinical strain AB5075-UW, and a complemented strain, we confirmed its role in the in vitro utilisation of l-(+)-lactate. Furthermore, disruption of the lactate metabolism pathway resulted in reduced bacterial fitness during an in vivo systemic murine competition assay. The disruption of lldP had no impact on the susceptibility of this strain to complement mediated killing by healthy human serum. However, growth in biologically relevant concentrations of lactate observed during severe sepsis, led to bacterial tolerance to killing by healthy human blood, a phenotype that was abolished in the lldP mutant. This study highlights the importance of the lactate metabolism pathway for survival and growth of A. baumannii during infection.
The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.